Adimab Newswire

Comprehensive Real-Time News Feed for Adimab.

Results 1 - 10 of 10 in Adimab

  1. Adimab Establishes New Partnership with Celgene for Discovery of...Read the original story

    Thursday May 7 | Freshnews

    Adimab, LLC, the technology leader in the discovery of fully human antibodies, today announced a new collaboration with Celgene, which follows an earlier 2013 agreement between the two parties. Under the terms of the new agreement, Adimab may generate novel common light chain libraries with Celgene and use its proprietary platform to generate IgGs against multiple targets.

    Comment?

  2. Adimab LLC. Announces New Bispecific Antibody Collaboration With SanofiRead the original story

    Feb 5, 2015 | BioSpace

    Feb. 6, 2015 - Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a multi-target discovery and optimization collaboration with Sanofi. Under the terms of the Agreement, Adimab will use its proprietary platform to generate bispecific molecules against multiple targets.

    Comment?

  3. Adimab Announces New Bispecific Antibody Collaboration with SanofiRead the original story

    Feb 6, 2015 | Sys-Con Media

    Adimab, LLC , the technology leader in the discovery of fully human antibodies and bispecifics, today announced a multi-target discovery and optimization collaboration with Sanofi. Under the terms of the Agreement, Adimab will use its proprietary platform to generate bispecific molecules against multiple targets.

    Comment?

  4. Neutralizing Cross-reactive Antibody Impacts 5 Staphylococcus Aureus CytotoxinsRead the original story

    Jan 22, 2015 | Scientific Blogging

    ... Arsanis' research team has drawn on its extensive infectious disease experience and the company's partnership with Adimab LLC (Lebanon, NH), a leading discovery platform company, to develop this unique cross reactive antibody which is incorporated ...

    Comment?

  5. Targeting 5 staphylococcus aureus cytotoxins using broadly neutralizing cross-reactive antibodyRead the original story w/Photo

    Jan 19, 2015 | Medical News Today

    Arsanis, Inc. scientists and their collaborators at Adimab, LLC have described a unique monoclonal antibody with the potential to treat Staphylococcus aureus infections through the simultaneous neutralization of multiple key toxins produced by S. aureus, including alpha-hemolysin and four additional leukocidins. The findings are published online in the journal mAbs and demonstrate superior in vitro potency compared to antibodies targeting alpha-hemolysin alone.

    Comment?

  6. Broadly neutralizing cross-reactive antibody targets 5 Staphylococcus aureus cytotoxinsRead the original story w/Photo

    Jan 14, 2015 | EurekAlert!

    Arsanis is developing this cross reactive antibody as part of its ASN100 product candidate, and aims to initiate human testing in 2015 LEBANON, NEW HAMPSHIRE AND VIENNA, AUSTRIA : Arsanis, Inc. scientists and their collaborators at Adimab, LLC have described a unique monoclonal antibody with the potential to treat Staphylococcus aureus infections through the simultaneous neutralization of multiple key toxins produced by S. aureus , including alpha-hemolysin and four additional leukocidins. The findings are published online this week in the journal mAbs and demonstrate superior in vitro potency compared to antibodies targeting alpha-hemolysin alone.

    Comment?

  7. Adimab LLC. Announces Expansion Of Its Collaboration With...Read the original story

    Jan 11, 2015 | BioSpace

    Adimab, LLC , a technology leader in the discovery of fully human antibodies and bispecifics, today announced that GlaxoSmithKline has broadened its relationship with Adimab. Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads.

    Comment?

  8. Adimab Announces Expansion of its Collaboration with GSK for the Discovery of Bispecific AntibodiesRead the original story

    Jan 12, 2015 | Business Wire

    Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads. Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets.

    Comment?

  9. Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and PotenzaRead the original story

    Jan 9, 2015 | Freshnews

    Adimab, LLC , the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner. "These new partnerships epitomize the growing trend of highly innovative discovery programs originating in smaller and mid-sized biotech companies," said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab.

    Comment?

  10. Adimab LLC. Announces New Partnerships With Acceleron Pharma, Oncothyreon Inc., AndRead the original story

    Jan 8, 2015 | BioSpace

    Achieves Milestones in Collaborations with Genentech, Merck & Co. and Others LEBANON, N.H. - Jan. 9, 2015 - Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.

    Comment?